Nebivolol Gp

Nebivolol, the active ingredient in Nebivolol Gp, is a beta blocker presented as a tablet for oral use. It lowers blood pressure and improves cardiac function in adults with hypertension or heart failure.

GNH USA supplies Nebivolol Gp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

- Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. - Chronic heart failure: improves left‑ventricular ejection fraction and decreases symptoms in patients with reduced‑ejection‑fraction heart failure. - Post‑myocardial infarction: assists in blood‑pressure control and reduces cardiac workload after an acute coronary event.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: generalized tiredness that may improve with continued use. - Bradycardia: heart rate below 60 bpm in some patients. - Nausea: occasional stomach upset or queasiness. - Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: significant drop in blood pressure causing faintness. - Heart block: conduction disturbances that may need pacing. - Bronchospasm: airway constriction, particularly in patients with asthma. - Allergic reactions: rash, itching, or swelling of the face and throat. - Liver enzyme elevation: abnormal hepatic function tests.

Before initiating Nebivolol, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: check regularly to ensure therapeutic control. - Heart rate assessment: observe for excessive bradycardia, especially in patients with conduction disorders. - Asthma or COPD caution: use carefully as β‑blockade may precipitate bronchospasm. - Concomitant beta‑blockers: avoid duplicate therapy to prevent additive effects. - Renal or hepatic impairment: dose adjustment may be required based on organ function. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several medication classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive cardiac depression. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): may cause severe bradycardia. - Alpha‑blockers (prazosin): risk of profound hypotension. - Antihypertensive combinations with high‑dose diuretics: excessive blood‑pressure drop.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor for additive hypotensive effect. - Diuretics: watch for electrolyte disturbances. - NSAIDs: may blunt antihypertensive response. - Antidiabetic agents: monitor blood glucose as beta‑blockade can mask hypoglycemia signs.